MedTrace Logo

The Compartmental Biology of HIV in the Male Genital Tract

NCT02638493 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 26

Last updated 2017-07-24

Study results available
· View outcomes & findings →

Summary

Male participants taking tenofovir-emtricitabine (TDF/FTC) will provide semen and blood samples which will be analyzed to better understand the pharmacology of antiretroviral therapy in the male genital tract.

Conditions

  • Human Immunodeficiency Virus
  • Virus Shedding

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • University of North Carolina, Chapel Hill

    lead OTHER

Principal Investigators

  • Julie Dumond, PharmD, MS · University of North Carolina, Chapel Hill

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02638493 on ClinicalTrials.gov